PE20080981A1 - Moduladores de receptor pth y usos de los mismos - Google Patents
Moduladores de receptor pth y usos de los mismosInfo
- Publication number
- PE20080981A1 PE20080981A1 PE2007001379A PE2007001379A PE20080981A1 PE 20080981 A1 PE20080981 A1 PE 20080981A1 PE 2007001379 A PE2007001379 A PE 2007001379A PE 2007001379 A PE2007001379 A PE 2007001379A PE 20080981 A1 PE20080981 A1 PE 20080981A1
- Authority
- PE
- Peru
- Prior art keywords
- leu
- xaa18
- xaa8
- arg
- val
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- XQFLFQWOBXPMHW-NHCYSSNCSA-N Asp-Val-His Chemical compound N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)O XQFLFQWOBXPMHW-NHCYSSNCSA-N 0.000 abstract 1
- 206010065687 Bone loss Diseases 0.000 abstract 1
- DYFJZDDQPNIPAB-NHCYSSNCSA-N Glu-Arg-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O DYFJZDDQPNIPAB-NHCYSSNCSA-N 0.000 abstract 1
- WVYJNPCWJYBHJG-YVNDNENWSA-N Glu-Ile-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O WVYJNPCWJYBHJG-YVNDNENWSA-N 0.000 abstract 1
- HGJREIGJLUQBTJ-SZMVWBNQSA-N Glu-Trp-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(O)=O HGJREIGJLUQBTJ-SZMVWBNQSA-N 0.000 abstract 1
- JPXNYFOHTHSREU-UWVGGRQHSA-N Gly-Arg-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CN JPXNYFOHTHSREU-UWVGGRQHSA-N 0.000 abstract 1
- JWTKVPMQCCRPQY-SRVKXCTJSA-N His-Asn-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O JWTKVPMQCCRPQY-SRVKXCTJSA-N 0.000 abstract 1
- OBSIQMZKFXFYLV-QMMMGPOBSA-N L-phenylalanine amide Chemical compound NC(=O)[C@@H](N)CC1=CC=CC=C1 OBSIQMZKFXFYLV-QMMMGPOBSA-N 0.000 abstract 1
- BQSLGJHIAGOZCD-CIUDSAMLSA-N Leu-Ala-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O BQSLGJHIAGOZCD-CIUDSAMLSA-N 0.000 abstract 1
- JNDYEOUZBLOVOF-AVGNSLFASA-N Leu-Leu-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O JNDYEOUZBLOVOF-AVGNSLFASA-N 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 102000006461 Parathyroid Hormone Receptors Human genes 0.000 abstract 1
- 108010058828 Parathyroid Hormone Receptors Proteins 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- JGUWRQWULDWNCM-FXQIFTODSA-N Ser-Val-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O JGUWRQWULDWNCM-FXQIFTODSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 108010050848 glycylleucine Proteins 0.000 abstract 1
- 108010025306 histidylleucine Proteins 0.000 abstract 1
- 229920001427 mPEG Polymers 0.000 abstract 1
- 230000011164 ossification Effects 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229940075993 receptor modulator Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
SE REFIERE A UN COMPUESTO MODULADOR DEL RECEPTOR DE LA HORMONA PARATIROIDEA QUE COMPRENDE LA SECUENCIA PEGILADA Ser Val Ser Glu Ile Gln Leu Xaa8 His Asn Leu Gly Arg His Leu Ala Ser Xaa18 Glu Arg Val Glu Trp Leu Arg (I) Leu Leu Gln Asp Val His Asn Phe-NH2 O SEC NO:6, DONDE Xaa8 y Xaa18 son Met o Nle Y mPEG ES MONOMETOXI POLIETILENGLICOL CON UN PESO MOLECULAR DE 1500 A 5500 DALTONES. DICHO COMPUESTO ES UTIL PARA EL TRATAMIENTO Y PREVENCION DE ENFERMEDADES QUE IMPLIQUEN PERDIDA OSEA, COMO LA OSTEOPOROSIS YA QUE INDUCE A LA FORMACION DE HUESO Y POR TANTO AUMENTA LA RESISTENCIA BIOMECANICA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82938306P | 2006-10-13 | 2006-10-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20080981A1 true PE20080981A1 (es) | 2008-07-19 |
Family
ID=38974655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007001379A PE20080981A1 (es) | 2006-10-13 | 2007-10-12 | Moduladores de receptor pth y usos de los mismos |
Country Status (12)
| Country | Link |
|---|---|
| AR (1) | AR063251A1 (es) |
| CL (1) | CL2007002876A1 (es) |
| CO (1) | CO6190624A2 (es) |
| CR (1) | CR10681A (es) |
| CY (1) | CY1110701T1 (es) |
| DE (1) | DE602007006839D1 (es) |
| ES (1) | ES2343917T3 (es) |
| MA (1) | MA30873B1 (es) |
| PE (1) | PE20080981A1 (es) |
| PT (1) | PT2084183E (es) |
| TW (1) | TW200817439A (es) |
| ZA (1) | ZA200901853B (es) |
-
2007
- 2007-09-11 TW TW096133901A patent/TW200817439A/zh unknown
- 2007-10-04 ES ES07843791T patent/ES2343917T3/es active Active
- 2007-10-04 PT PT07843791T patent/PT2084183E/pt unknown
- 2007-10-04 DE DE602007006839T patent/DE602007006839D1/de active Active
- 2007-10-05 CL CL200702876A patent/CL2007002876A1/es unknown
- 2007-10-11 AR ARP070104507A patent/AR063251A1/es unknown
- 2007-10-12 PE PE2007001379A patent/PE20080981A1/es not_active Application Discontinuation
-
2009
- 2009-03-16 ZA ZA200901853A patent/ZA200901853B/xx unknown
- 2009-03-20 CR CR10681A patent/CR10681A/es not_active Application Discontinuation
- 2009-04-07 CO CO09035909A patent/CO6190624A2/es not_active Application Discontinuation
- 2009-05-07 MA MA31851A patent/MA30873B1/fr unknown
-
2010
- 2010-06-18 CY CY20101100569T patent/CY1110701T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR10681A (es) | 2009-07-13 |
| TW200817439A (en) | 2008-04-16 |
| PT2084183E (pt) | 2010-07-16 |
| CO6190624A2 (es) | 2010-08-19 |
| AR063251A1 (es) | 2009-01-14 |
| CY1110701T1 (el) | 2015-06-10 |
| ZA200901853B (en) | 2010-05-26 |
| MA30873B1 (fr) | 2009-11-02 |
| ES2343917T3 (es) | 2010-08-12 |
| CL2007002876A1 (es) | 2008-06-06 |
| DE602007006839D1 (de) | 2010-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20141546A1 (es) | Anticuerpos anti-cd134(ox40) y sus usos de los mismos | |
| ECSP12012351A (es) | Análogos de glucagón | |
| CO7400885A2 (es) | Análogos de glucagón | |
| ECSP12011593A (es) | Análogos de glucagón acilados | |
| PH12018502538A1 (en) | Antibodies to alpha-synuclein and uses thereof | |
| AR075989A1 (es) | Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria | |
| GB2564823A (en) | Compositions and methods for T-cell receptors reprogramming using fusion proteins | |
| MX2016004907A (es) | Analogos del glucagon. | |
| CO6660483A2 (es) | Análogos de glucagón | |
| CO2017000614A2 (es) | Polipéptidos gdf15 modificados y composiciones de los mismos | |
| PE20141166A1 (es) | Anticuerpos anti-angptl3 y usos de los mismos | |
| PE20141045A1 (es) | Proteinas de union a bcma (cd269/tnfrsf17) | |
| ECSP077894A (es) | Antagonistas de npy, preparación y usos | |
| CO6220870A2 (es) | Prediccion de respuesta a un inhibidor a un inhibidor de dimerizacion her basado en expresion de her3 bajo | |
| PE20140186A1 (es) | Analogos de glucagon que presentan actividad de receptor de gip | |
| MX2011006315A (es) | Analogos de glucagon. | |
| MY160219A (en) | Glucagon analogues | |
| MX2011006320A (es) | Analogos de glucagon. | |
| CO6361994A2 (es) | Antagonistas del receptor de orexina de isonicotinamida | |
| NZ751746A (en) | Combination therapy with controlled-release cnp agonists | |
| PE20220488A1 (es) | Variantes del cnp y sus conjugados | |
| CU20210099A7 (es) | Anticuerpos de receptor de péptido natriurético 1 | |
| SV2004001417A (es) | Composiciones famaceuticas y procedimientos para administrar agonistas selectivos del receptor ep2 ref. pc10465 | |
| BRPI0519031A2 (pt) | compostos e composiÇÕes como moduladores de atividades de receptores esteroidais e de canal de cÁlcio | |
| PT1988914E (pt) | Combinação de análogos de somatostatina com diferente selectividade para subtipos do receptor da somatostatina humana |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |